1. Academic Validation
  2. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist

  • J Med Chem. 2002 Oct 10;45(21):4589-93. doi: 10.1021/jm025539h.
Iyassu K Sebhat 1 William J Martin Zhixiong Ye Khaled Barakat Ralph T Mosley David B R Johnston Raman Bakshi Brenda Palucki David H Weinberg Tanya MacNeil Rubana N Kalyani Rui Tang Ralph A Stearns Randy R Miller Constantin Tamvakopoulos Alison M Strack Erin McGowan Doreen E Cashen Jennifer E Drisko Gary J Hom Andrew D Howard D Euan MacIntyre Lex H T van der Ploeg Arthur A Patchett Ravi P Nargund
Affiliations

Affiliation

  • 1 Department of Chemistry, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065-0900, USA. iyassu_sebhat@merck.com
Abstract

Synthetic and natural Peptides that act as nonselective Melanocortin Receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

Figures
Products